Next Article in Journal
Anti-Diabetic Countermeasures Against Tobacco Smoke-Dependent Cerebrovascular Toxicity: Use and Effect of Rosiglitazone
Next Article in Special Issue
MicroRNA Networks Modulate Oxidative Stress in Cancer
Previous Article in Journal
Loss of Glycine N-Methyltransferase Associates with Angiopoietin-Like Protein 8 Expression in High Fat-Diet-Fed Mice
Previous Article in Special Issue
miR526b and miR655 Induce Oxidative Stress in Breast Cancer
Open AccessReview

Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment

Oncology Pathology, Department of Pathology and Host-Defense, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(17), 4224; https://doi.org/10.3390/ijms20174224
Received: 26 July 2019 / Revised: 24 August 2019 / Accepted: 27 August 2019 / Published: 29 August 2019
Approximately 30% of pancreatic cancer patients harbor targetable mutations. However, there has been no therapy targeting these molecules clinically. Nucleic acid medicines show high specificity and can target RNAs. Nucleic acid medicine is expected to be the next-generation treatment next to small molecules and antibodies. There are several kinds of nucleic acid drugs, including antisense oligonucleotides, small interfering RNAs, microRNAs, aptamers, decoys, and CpG oligodeoxynucleotides. In this review, we provide an update on current research of nucleic acid-based therapies. Despite the challenging obstacles, we hope that nucleic acid drugs will have a significant impact on the treatment of pancreatic cancer. The combination of genetic diagnosis using next generation sequencing and targeted therapy may provide effective precision medicine for pancreatic cancer patients. View Full-Text
Keywords: nucleic acid medicine; pancreatic cancer; clinical trial; siRNA; antisense oligonucleotide nucleic acid medicine; pancreatic cancer; clinical trial; siRNA; antisense oligonucleotide
Show Figures

Figure 1

MDPI and ACS Style

Yamakawa, K.; Nakano-Narusawa, Y.; Hashimoto, N.; Yokohira, M.; Matsuda, Y. Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment. Int. J. Mol. Sci. 2019, 20, 4224.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop